An updated atlas of antibody evasion by SARS-CoV-2 Omicron sub-variants including BQ.1.1 and XBB

被引:41
|
作者
He, Qingwen [1 ,2 ]
Wu, Lili [2 ]
Xu, Zepeng [2 ,3 ]
Wang, Xiaoyun [2 ,3 ]
Xie, Yufeng [2 ,4 ]
Chai, Yan [2 ]
Zheng, Anqi [2 ]
Zhou, Jianjie [2 ]
Qiao, Shitong [2 ]
Huang, Min [2 ,5 ]
Shang, Guijun [6 ]
Zhao, Xin [2 ]
Feng, Youjun [1 ]
Qi, Jianxun [2 ]
Gao, George Fu [1 ,2 ,3 ,7 ]
Wang, Qihui [2 ,3 ]
机构
[1] Zhejiang Univ, Sch Med, Dept Microbiol, Hangzhou 310058, Zhejiang, Peoples R China
[2] Chinese Acad Sci, Inst Microbiol, CAS Key Lab Pathogen Microbiol & Immunol, Beijing 100101, Peoples R China
[3] Univ Chinese Acad Sci, Beijing 100049, Peoples R China
[4] Tsinghua Univ, Sch Med, Dept Basic Med Sci, Beijing 100084, Peoples R China
[5] Univ Sci & Technol China, Sch Life Sci, Hefei 230026, Anhui, Peoples R China
[6] Shanxi Acad Adv Res & Innovat, Taiyuan 030032, Shanxi, Peoples R China
[7] Chinese Ctr Dis Control & Prevent, Beijing 102206, Peoples R China
基金
中国博士后科学基金; 中国国家自然科学基金;
关键词
MUTATION;
D O I
10.1016/j.xcrm.2023.100991
中图分类号
Q2 [细胞生物学];
学科分类号
071009 ; 090102 ;
摘要
Emerging Omicron sub-variants are causing global concerns, and their immune evasion should be monitored continuously. We previously evaluated the escape of Omicron BA.1, BA.1.1, BA.2, and BA.3 from an atlas of 50 monoclonal antibodies (mAbs), covering seven epitope classes of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) receptor-binding domain (RBD). Here, we update the atlas of totally 77 mAbs against emerging sub-variants including BQ.1.1 and XBB and find that BA.4/5, BQ.1.1, and XBB display further evasion. Besides, investigation into the correlation of binding and neutralization of mAbs reveals the important role of antigenic conformation in mAb functioning. Moreover, the complex structures of BA.2 RBD/BD-604/S304 and BA.4/5 RBD/BD-604/S304/S309 further elucidate the molecular mechanism of antibody evasion by these sub-variants. By focusing on the identified broadly potent mAbs, we find a general hotspot epitope on the RBD, which could guide the design of vaccines and calls for new broad-spec-trum countermeasures against COVID-19.
引用
下载
收藏
页数:18
相关论文
共 50 条
  • [31] Human Anti-SARS-CoV-2 Tetravalent Bispecific Antibody Broadly Neutralizes Major Variants of Concern Including Omicron Sub-Variants
    Chiyyeadu, Abhishek
    Asgedom, Girmay
    Bruhn, Matthias
    Rocha, Cheila
    Galla, Melanie
    Ehrhardt, Katrin
    Morgan, Michael
    Poehlmann, Stefan
    Kalinke, Ulrich
    Schambach, Axel
    MOLECULAR THERAPY, 2023, 31 (04) : 685 - 686
  • [32] Low neutralization of SARS-CoV-2 Omicron BA.5.2.48 and XBB.1 sub-variants in response to breakthrough infection by booster
    Li, Jianhua
    Gong, Liming
    Li, Jiaxuan
    Gong, Zhenyu
    Wang, Xiaoxiao
    Yan, Hao
    Zhang, Yanjun
    Mao, Haiyan
    Chen, Keda
    VACCINE, 2024, 42 (18) : 3751 - 3755
  • [33] Evasion of vaccine-induced humoral immunity by emerging sub-variants of SARS-CoV-2
    Koyama, Takahiko
    Miyakawa, Kei
    Tokumasu, Reitaro
    Jeremiah, Sundararaj S.
    Kudo, Michiharu
    Ryo, Akihide
    FUTURE MICROBIOLOGY, 2022, 17 (06) : 417 - 424
  • [34] Deep mutational scans of XBB.1.5 and BQ.1.1 reveal ongoing epistatic drift during SARS-CoV-2 evolution
    Taylor, Ashley L.
    Starr, Tyler N.
    PLOS PATHOGENS, 2023, 19 (12)
  • [35] Engineered Multivalent Nanobodies Efficiently Neutralize SARS-CoV-2 Omicron Subvariants BA.1, BA.4/5, XBB.1 and BQ.1.1
    Wang, Jiali
    Shi, Bingjie
    Chen, Hanyi
    Yu, Mengyuan
    Wang, Peipei
    Qian, Zhaohui
    Hu, Keping
    Wang, Jianxun
    VACCINES, 2024, 12 (04)
  • [36] Low neutralization of SARS-CoV-2 Omicron BA.2.75.2, BQ.1.1 and XBB.1 by parental mRNA vaccine or a BA.5 bivalent booster
    Kurhade, Chaitanya
    Zou, Jing
    Xia, Hongjie
    Liu, Mingru
    Chang, Hope C.
    Ren, Ping
    Xie, Xuping
    Shi, Pei-Yong
    NATURE MEDICINE, 2023, 29 (02) : 344 - 347
  • [37] Neutralization of SARS-CoV-2 BQ.1.1, CH.1.1, and XBB.1.5 by breakthrough infection sera from previous and recent waves in China
    Wang, Xun
    Jiang, Shuai
    Jiang, Shujun
    Li, Xiangnan
    Ai, Jingwen
    Lin, Ke
    Lv, Shiyun
    Zhang, Shixuan
    Li, Minghui
    Li, Jixi
    Dai, Lili
    Hu, Zixin
    Zhang, Wenhong
    Zhang, Yanliang
    Wang, Pengfei
    CELL DISCOVERY, 2023, 9 (01)
  • [38] Sotrovimab retains activity against SARS-CoV-2 omicron variant BQ.1.1 in a non-human primate model
    Herate, Cecile
    Marlin, Romain
    Touret, Franck
    Dereuddre-Bosquet, Nathalie
    Donati, Flora
    Relouzat, Francis
    Junges, Laura
    Galhaut, Mathilde
    Dehan, Oceane
    Sconosciuti, Quentin
    Nougairede, Antoine
    de Lamballerie, Xavier
    van der Werf, Sylvie
    Le Grand, Roger
    HELIYON, 2023, 9 (06)
  • [39] Neutralization of SARS-CoV-2 BQ.1.1, CH.1.1, and XBB.1.5 by breakthrough infection sera from previous and recent waves in China
    Xun Wang
    Shuai Jiang
    Shujun Jiang
    Xiangnan Li
    Jingwen Ai
    Ke Lin
    Shiyun Lv
    Shixuan Zhang
    Minghui Li
    Jixi Li
    Lili Dai
    Zixin Hu
    Wenhong Zhang
    Yanliang Zhang
    Pengfei Wang
    Cell Discovery, 9
  • [40] Antibody evasion properties of SARS-CoV-2 Omicron sublineages
    Sho Iketani
    Lihong Liu
    Yicheng Guo
    Liyuan Liu
    Jasper F.-W. Chan
    Yiming Huang
    Maple Wang
    Yang Luo
    Jian Yu
    Hin Chu
    Kenn K.-H. Chik
    Terrence T.-T. Yuen
    Michael T. Yin
    Magdalena E. Sobieszczyk
    Yaoxing Huang
    Kwok-Yung Yuen
    Harris H. Wang
    Zizhang Sheng
    David D. Ho
    Nature, 2022, 604 : 553 - 556